Home > Oncology > ESMO 2021 > Genitourinary Cancer > Better survival with neoadjuvant dose-dense MVAC regimen in MIBC

Better survival with neoadjuvant dose-dense MVAC regimen in MIBC

Presented By
Dr Christian Pfister, Rouen University Hospital, France
ESMO 2021
Phase 3, VESPER
Dose-dense MVAC outperforms gemcitabine/cisplatin as neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC), results from the phase 3 VESPER trial showed. The optimal neoadjuvant chemotherapy regimen for patients with MIBC is not defined. Therefore, the VESPER trial (NCT01812369) randomised 493 MIBC patient 1:1 to either 4 cycles of gemcitabine/cisplatin every 3 weeks or 6 cycles of dose-dense methotrexate/vinblastine/doxorubicin/cisplatin (dd-MVAC) every 2 weeks, before surgery. Primary endpoint was progression-free survival (PFS) at 3 years. Dr Christian Pfister (Rouen University Hospital, France) presented the results [1]. A total of 437 patients (88%) received neoadjuvant chemotherapy, 56 patients (12%) received adjuvant chemotherapy; 60% patients received all planned 6 cycles in the dd-MVAC arm and 84% received all 4 cycles in ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on